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Abstract: Cancer is one of the greatest life-threatening diseases conventionally treated using chemo-
and radio-therapy. Photodynamic therapy (PDT) is a promising approach to eradicate different types
of cancers. PDT requires the administration of photosensitisers (PSs) and photoactivation using a
specific wavelength of light in the presence of molecular oxygen. This photoactivation exerts an
anticancer effect via apoptosis, necrosis, and autophagy of cancer cells. Recently, various natural
compounds that exhibit photosensitising potentials have been identified. Photoactive substances
derived from medicinal plants have been found to be safe in comparison with synthetic compounds.
Many articles have focused on PDT mechanisms and types of PSs, but limited attention has been
paid to the phototoxic activities of phytocompounds. The reduced toxicity and side effects of natural
compounds inspire the researchers to identify and use plant extracts or phytocompounds as a potent
natural PS candidate for PDT. This review focusses on the importance of common photoactive groups
(furanocoumarins, polyacetylenes, thiophenes, curcumins, alkaloids, and anthraquinones), their
phototoxic effects, anticancer activity and use as a potent PS for an effective PDT outcome in the
treatment of various cancers.
Keywords: photodynamic therapy; cancer; photosensitiser; natural compounds
1. Introduction
Cancer is one of the deadliest diseases reported in developed as well as developing countries [1].
It is mainly characterised by the uncontrolled cell growth and development of normal cells due to
genetic alterations or exposure to the carcinogenic substances. The mutation of normal cells leads to
abnormal cellular proliferation and develops into tumour [2]; this can be either benign, premalignant
(non-cancerous) or malignant (cancerous) [3,4]. Presently surgery, radiotherapy, and chemotherapy
either as monotherapy or as combined treatments are used in the treatment of cancer. However, these
treatments frequently stimulate redundant side effects [2]. Many of the current chemotherapeutic
drugs are of low molecular weight with high pharmacokinetic profiles [4]. Hence, in order to achieve
the bioavailability and cytotoxicity induction, the drugs are administrated in high concentrations.
In photodynamic therapy (PDT), photoactive drugs are generally administered systemically, but because
of the precise application of light from the laser source, the cytotoxicity is attained in the tumour
location. Due to the lesser drug specificity and toxicity to healthy cells, the chemotherapeutic drugs
used in cancer treatments need to be improved.
Photodynamic therapy (PDT) is a promising minimally invasive therapy for the treatment of
cancer. This involves the administration of photosensitiser (PS) and subsequent excitation of PS
by light irradiation at a specific wavelength. The excited PS then reacts with cellular oxygen and
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produces reactive oxygen species (ROS). This reaction results in oxidising the cellular macromolecules
surrounding tumour cells [5]. This remedial method has been developed over the last few years [6,7],
and has not only been utilised in cancer treatment, but also in dermatological [8] and ophthalmic [9]
conditions, including psoriasis and age-related diseases [10–12]. The use of photodynamic therapy
to treat cancers has gained attention around the world [13,14]. The mechanism of PDT is based on
various photocatalytic reactions that induce the destruction of cancer cells, and it has been clinically
used for the treatment of cancer for over a decade [5]. In the first clinical PDT study reported by
Granelli et al. [15], hematoporphyrin was used as a potent photosensitiser (PS) against glioma cancer
cells. PDT destroys cancer cells through three fundamentally different pathways, namely, by damaging
cancer cells over time, damaging vascular tissues that supply oxygen to cells, and finally by activating
host immune response systems [13,16]. Combining PDT with chemotherapy, radiotherapy, and herbal
therapy could be an emerging future methodology in cancer treatment. The combination therapy
has more of a tendency to reduce the side effects when compared to monotherapy regimes and can
significantly lower cancer cell proliferation by improving the drug uptake [17].
Since ancient times, herbal medicine from natural products has been utilised for treating various
human ailments [18]. Most current medicines are derived from various medicinal plants, and it
is evident that herbal extracts and their compounds should be examined as possible active lead
components in cancer drug discoveries [19,20]. Nature is a valuable reserve for medicinal plants,
and many of the pharmaceutically active compounds isolated from medicinal plants have not been
tested for photoactive properties. There have been few studies attempting to identify new chemical
compounds with photoactivity from plant extracts that can be used as potent natural PSs [21–25].
Hypericin (isolated from Hypericum perforatum) is a recognised plant-based PS used in PDT. The in vitro
and in vivo studies reported that hypericin PS activated at 594 nm could destroy cancer cell proliferation
effectively. The researchers already demonstrated that the effect of herbal extracts combined with
illumination could significantly reduce cancer development by prohibiting metabolic viability and
proliferation cancer cells [26–29].
Due to the low or no adverse side effects, herbal products have been used for the treatment of
many more ailments than synthetic drugs. Studies have shown that plant-based compounds could
be used in the treatment of various cancers [30]. Many phototoxic substances were subsequently
reported in various plant species that are equally efficient as of conventional PSs [31]. These studies
recommend that natural compounds with photosensitising abilities can be isolated from plants and
used as alternatives for conventional PSs used in PDT. In this review, the underlying principles of
PDT, PSs and plant-based photoactive compounds were addressed. This review mainly focused on
the anticancer activity of furanocoumarins, polyacetylenes, thiophenes, curcumins, alkaloids and
anthraquinones in relation to the light-absorbing properties.
2. Basic Principles of Photodynamic Therapy
Photodynamic therapy involves coordination with three individual factors, namely, the photosensitiser,
oxygen, and light [7]. These components are not toxic to cells individually, but when irradiated, these can
initiate a photochemical reaction that generates highly reactive singlet oxygen (1O2) and cause significant
toxicity, leading to cell death. PDT is normally described in two stages, the first is administration of the
PS and the second stage is the irradiation. Generally, the effect of PDT is affected by the PS type, dosage,
light fluence, as well as exposure time. PDT can be used either before or after chemotherapy, radiotherapy,
or surgery without compromise. The clinically approved PS should not accumulate in the body and does
not develop resistant cancer cells. Pain during administration and continuous photosensitisation are the
major drawbacks of PDT treatment. There are three types of lights ranges from 600 to 800 nm that are
commonly used in PDT, namely, blue, red, and infrared lights. Among them, blue light penetrates the tissue
the least when compared to red and infrared lights. The wavelengths below 800 nm are mostly used in PDT
than higher wavelengths (above 800 nm) due to their lack of photodynamic reactions. The choice of light
Molecules 2020, 25, 4102 3 of 22
source is commonly based on PS nature, absorption spectra of PS, location, and size and characteristics of
the infected tissue [7,32].
More than 300 chemical compounds have already been identified as potential candidates to be
used as PSs. Amongst these, a few were authorised for clinical application in PDT, and others were
medically evaluated, whereas some are still under examination [33,34]. We have tabulated some PSs
which are used in various cancer treatments in Table 1. Photosensitisers are naturally or chemically
produced compound conjugated with a visible light-absorbing chromophore group with a strong
chemical absorbance. Choosing the correct PS is the most important phase in PDT for a successful
outcome [33,34]. The purity and the presence of a tetrapyrrole structure with good storage stability are
the preferable properties of most PSs used in PDT. The potent and effective PS should have the ability
to initiate a photodynamic reaction after irradiation with 600–800 nm lights and should not cause any
toxicity under dark conditions. It should be easily distinguishable from the body with no or minimum
phototoxic side effects [35]. The better diffusion of PS through the cells after long administration
might contribute to the effectiveness of PDT [36]. The production of a significant amount of ROS after
irradiation that induces apoptosis with less inflammation is most likely to be a suitable PS for PDT
application [37,38].
When a PS is subjected to a particular wavelength light, the electron of the outermost orbital will
be shifted from the ground state (S0) to the first excited state (S1). Subsequently, the electromagnetic
propulsion switches the molecule to an excited triplet state (T1) with a longer life span (Figure 1).
In each of these excited states, PSs are quite unstable and lose their energy in the form of fluorescence,
phosphorescence, and internal heat conversion. PSs in the T1 state may react photochemically in any
of the two pathways. In the type 1 pathway, the excited PS reacts through an electron transfer process
with the surrounding oxygen, which ultimately leads to generation of reactive oxygen species (ROS).
Such free radicals communicate readily with the biomolecules (lipids, peptides, proteins, and nucleic
acids) and destroy them [39,40]. In contrast, in the type 2 pathway, the energy is directly transferred
from the T1 state of the PS to the S0-state oxygen. This results in the ground-state PS transformation
and excited-state singlet reactive oxygen. The disruption caused by PDT is local because both singlet
oxygen as well as free radicals have a short half-life between 10–300 nanoseconds and a small diffusion
distance of 10–55 nm [41].
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Table 1. List of photosensitisers used in photodynamic therapy of various cancers.
Photosensitiser Commercial Name λ max (nm) Structure Type of Cancer Reference
First-Generation Photosensitiser
Hematoporphyrin derivatives Photofrin Photoheme 630
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Table 1. Cont.
Photosensitiser Commercial Name λ max (nm) Structure Type of Cancer Reference
Benzoporphyrin Visudyne 690
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3. PDT’s Cancer Cell Death Mechanism
PDT’s cancer cell death mechanism starts after the activation of administrated PS by a specific
wavelength of light. The PS’s hydrophilic, hydrophobic, and ionic charge-related interaction nature
plays an important role in the targeting of particular cancer cell receptor (globulins and Low-Density
Lipoprotein (LDL) receptors) [34]. After the activation of PSs, the cancer cell death mechanism
might occur in three main pathways (Figure 1), namely, apoptosis, necrosis, and autophagy [33,65,66].
However, the level of cell death induced by PDT may be affected by various aspects, including
subcellular localisation, bioavailability, the physicochemical nature of the PS, the cellular oxygen
concentration, as well as the applied light intensity and wavelength [67]. In general, the light-absorbed
PS interacts with cellular oxygen and highly produce ROS (hydroperoxides, superoxide, or hydroxyl
radicals) as well as singlet oxygen (1O2). These produced ROS can induce cancerous cell death via the
above-mentioned mechanisms. Both type 1 and 2 reactions may occur separately or in combination,
but type 1 (generation of ROS followed by the apoptotic cell death mechanism) is commonly exhibited
by most approved PSs [67].
4. PS from Natural Resources
The effectiveness of PDT is mainly based on the PS; it should possess all the properties of the PS as
previously explained. The PS can be divided into first- and second-generation types. Hematoporphyrin
and its derivative Photofrin®® were classified as first-generation PSs. After extensive studies, new and
improved second-generation PSs, such as Levulan®®, Alasens®®, and Foscan have been introduced
for PDT application (Table 1). Although these are widely used for various cancer treatments, their
clinical usage is limited by various drawbacks such as lack of chemical purity, a longer half-life,
accumulation in tissues and poor ability in relation to depth of tissue penetration [31–39].
Subsequently, there are some research reports on PSs with potent pharmaceutical properties
to overcome the shortcomings of first- (Porphyrin based sensitisers) and second-generation
(non-porphyrin derivatives) PSs [35–37]. These drawbacks of current PSs specifically imply the
need for new PSs as anticancer agents from natural resources. The discovery of new PS compounds
with anticipated pharmacological properties and clinical application is an inspiring task. Recently,
a greater number of plant-based compounds have been reported for their anticancer activity, and these
compounds are pharmaceutically very important for the development of potent drugs. The use of light
to activate the bioactivities of natural products is generally called photopharmacology (a combination
of photophysics and photochemistry). The absorption of lights (λ < 350 nm) by a molecule mainly
depends on the chromophore compound attached (Figure 2) [36,37]. This review presents an overview
of natural photoactive compounds as potent third-generation photosensitisers in the improvement of
PSs in relation to their prospective application in cancer treatments.
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5. Natural Photoactive Compounds from Plants
The search for the natural compounds as efficient PSs has been progressively moving forward
because of the side effects caused by current synthetic drugs. The advanced isolation, identification
and characterisation techniques improved the extraction of desirable compounds from plants. Recently,
using these advanced techniques, the isolation of natural photoactive compounds has become
easy. Although there have been few studies attempting to identify new chemical compounds with
photoactivity from plant extracts, this review discusses the photoactivity as well as the anticancer activity
of some plant-based compounds such as furanocoumarins, polyacetylenes, thiophenes, curcumins,
alkaloids and anthraquinones (Table 2).
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Table 2. List of plant-based natural photoactive compounds with known photoactivity.
Name Absorption Maxima Chemical Property and Groups Natural Sources Possible Mode of Action Reference
Furanocoumarins 333 nm Aromatic compounds possessing afuran ring.
Angelicae dahuricae, Tetradium daniellii,
Glehnia littoralis, Heracleum persicum,
Syzygium Sps, Ruta graveolens, Ficus sps.
DNA intercalation under dark
type 2 PDT reaction.
Crosslinking and adduct
formation with DNA and RNA.
Cell membrane damage.
[68–70]
Polyacetylenes and Thiophenes 488 nm
Furanoacetylenes thiarubrines,
thiophenes, polyacetylene
(aliphatic compounds with more
than three conjugated triple bonds),
thiophenes (aromatic acetylenes;
e.g., phenylheptatriyne).
Asteraceae spp, Heliopsisa, Rudbeckia spp,
Arnica, Centaurea scabiosa, Tagetes erecta,
Porophyllum obscurum, Echinops, Bidens,
Ambrosia chamissonis, T. minuta, E.
latifolius, E. sgrijissi, Rhaponticum
uniflorum.
Membrane damage or
erythrocyte leakage;
type 1 and type 2 PDT reaction,
as well as type 1 and 2 PDT
mixed reaction.
[71–75]
Curcumins 420–480 nm
Dicinnamoylmethane, curcumin,
curcuminoids,
demethoxycurcumin,
bisdemethoxycurcumin.
Curcuma longa.
Cell membrane is the primary
target of curcuminoids.
Induction of caspase-mediated
cell death.
[76–78]
Alkaloids 360 nm
Chinolin alkaloids, pterins,
benzylisoquinolines,
beta-carbolines, harmine.
Guatteria blepharophylla, Berberis vulgaris,
Sanguinaria Canadensis, Mahonia
aquifolium
Peganum harmala, Indigofera tinctoria.
Photo-oxidises histidine and
tryptophan, resulting in DNA
crosslinking.
Photooxidation, type 1 PDT
mechanism and targets
mitochondria.
[79–87]
Anthraquinones 437 nm
Hydroxyanthraquinones, rhein,
physcion, emodin, rubiadin,
damnacanthol, soranjidiol, alizarin,
purpurin, rubiadin, aloe-emodin,
1,5-dihydroxy przewalsquinone B,
ziganein, uredinorubellins,
caeruleoramularin, hypericin,
cercosporin, elsinochromes A-C
pleichrome, hypocrellin.
Polygonum cuspidatum, Heterophyllaea
pustulata, H. lycioides
Aloe vera, Rheum palmatum, Rumex crispus
Polyathia suberosa, Dactylopius coccus,
Xanthoria parietina, Drechslera avenae,
Ramularia collo-cygni.
H. perforatum, Fagopyrum esculentum.
Type 1 and 2 PDT action. [88–91]
Molecules 2020, 25, 4102 9 of 22
5.1. Furanocoumarins
The secondary metabolites, furanocoumarins (FC; Figure 3), are mostly present in higher plants.
The photoactive furanocoumarins were mainly composed of a linear core, and the biological distribution,
photochemistry and phototoxicity mechanisms of FC after PUVA (psoralen and long-wave ultraviolet
radiation) irradiation were reported in previous study [92]. In terms of phototherapy, psoralen is
activated in the wavelength range of 300–400 nm ultraviolet radiation to treat psoriasis, dermatitis,
eczema, and other skin problems [92]. Over a few years, many researchers reported anticancer activity
of FCs against various types of cancer such as breast, skin, and leukaemia. FCs modulate several
pathways inducing cancer cell death by inhibiting signal transducer and activator of transcription
3 (STAT3), nuclear factor-κB (NF-κB), phosphatidylinositol-3-kinase and AKT protein expression
(Figure 4). These pathways play a key role in tumour development through regular activation of
several inflammatory genes. Studies show that FC displayed potent activity against breast cancer
development by inhibiting STAT3 protein expression [93]. Panno et al. [92,93], demonstrated inhibition
of breast cancer cell growth in a dose-dependent manner through activation of p53 and Bax, leading to
the cleavage of caspase 9. In contrast, in leukaemia cells, FC inactivated the JAK (Janus-activated
kinase), protein c-Src, and STAT3, and downregulated Bcl-xl and Bcl-2 proteins which are responsible
for apoptosis [93–96]. The enhanced activity against the malignant melanoma cell line (A375) after
UV irradiation of plant extracts containing FC also supported the possible photoactive nature of
FCs [93–96]. The linear forms of furanocoumarins like psoralen and its derivatives 5-methoxypsoralen
(5-MOP) and 8-methoxypsoralen (8-MOP) are reported to increase the cytotoxicity after irradiation
by ultraviolet light in the 320–400 nm wavelength range against cutaneous T-cell lymphoma [97,98],
and photoactivated psoralens induce apoptosis by forming adducts with DNA. This leads to the
activation of p21waf/Cip and p53 and subsequently leads to cell death by the release of mitochondrial
cytochrome c. The photoactivation of psoralen can also cause cell death by blocking oncogenic receptor
tyrosine kinase signalling and the PI3K pathway by interfering with efficient recruitment of effector
Akt kinase to the activated plasma membrane [92–104]. PUVA treatment was found effectively against
B16F10 murine melanoma cells by cell cycle arrest in G2/M phases [93–96].
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5.2. Polyacetylene and Thiophenes
These group compounds are characterised by a triple bond carbon–carbon molecule [75] and
thiophenes compounds. Generally, the aliphatic compounds conjugated with three or more acetylenic
bonds are considered phototoxic in nature. Among these, polyacetylenes compounds can produce
1O2 under irradiation and thiophenes can provide high photo yield, leading to type 2 PDT reaction
yields [105]. The polyacetylene and thiophenes compounds were reported to be activated or excited at
a wavelength range of 314–350 nm absorbance maximum for the relevant photobiological effects [75].
The derivatives of these compounds were reported with a variety of potent biological activities,
including analgesic, anti-inflammatory, antitumour, and antimicrobial activities. Some of the derivatives
substituted by pyrimidines show antimicrobial, anti-inflammatory, and antitumour activities. A few
numbers of thiophenes were reported for their cytotoxic effects against human cancer cell lines. Echinops
grijisii root-derived thiophenes exhibited cytotoxicity against HL-60, K562 and MCF-7 cells [106].
Notably, derivatives such as thioxopyrimidine and thiazolopyrimidine were reported to possess
anticancer activities against MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer),
and SF-268 (CNS cancer) cells. These acetylenic compounds and derivatives when combined with
PDT might improve the efficacy of various cancer treatments [107–112]. The UV irradiation of some
thiophenes also showed increased cytotoxic activities [113]; this might be due to their instable nature
under UV radiation. Hence, the UV irradiation of polyacetylene and thiophene compounds can form
free radicals that would induce cell death. Due to the ability to produce ROS after irradiation, these
compounds can be used as an alternative PS from natural sources.
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5.3. Curcumins
Curcumin (CU) is a plant-based therapeutic compound isolated from rhizome of Curcuma longa of
the Zingiberaceae family. Curcuminoid is one of the most extensively studied plant-derived bioactive
compounds [114]. Since the 1980s, the photobiological potential of CU was of great interest [115,116],
and studies described CU as a desirable, highly promising photosensitiser [115,117–121]. The foremost
property of CU is that it is biologically safe even at higher doses, and it can be easily produced on
a large scale [117,122]. The photobleaching analysis reported the degradation profile of curcumin
derivatives and its ability to produce singlet oxygen species [123]. CU was characterised by an
absorption spectrum of 300–500 nm with a high extinction coefficient. This suggests that CU can
induce a strong phototoxic reaction even at lower concentrations [124–126]. Curcumin is considered
as a potential anticancer agent and inhibits cancer cell proliferation in breast, lung, colon, kidney,
ovary, and liver cancers [114]. The in vitro and in vivo anticancer activity of curcumin has been
proved by inhibition of various transcription factors such as NF-κB, AP-1, VEGF, iNOS, COX-2, 5-LOX,
MMP-2, MMP-9 and IL-8, which are mainly responsible for angiogenesis and tumour growth [127,128].
The administration of curcumin significantly reduced the expression of the CDK4/cylin D1 complex by
inhibiting p53 expression and causing the apoptotic process by inducing ROS generation. Furthermore,
the enhanced antitumour activity was noted after UVB irradiation of curcumin by caspase activation
on HaCaT (human keratinocyte cell) cells. It was also efficient against MCF-7 breast cancer cells at
30 J/cm2 [77,78]. These data suggested that curcumin may act as a potent anticancer agent by preventing
cancer progression, migration and invasion [129–131]. Dovigo et al. [132] found the light absorption
ability of CU in the range of 300 and 500 nm with a maximum absorption at 430 nm, which might
support its usage as a PS. The ROS-inducing and anticancer ability of CU makes it a potent candidate
as a natural PS [133]. Nevertheless, Chan and Wu [134] observed that the photoactive nature of CU
on human epidermal A431 carcinoma cells and the higher amount of CU also affect the irradiation
penetration [132,134,135]. The irradiation of CU under a 290–320 nm UVB light source with the fluence
of 100 mJ/cm2 induced apoptosis in HaCaT keratinocyte cells [78]. Based on the above reports, CU can
be used as a natural PS, and it can achieve high efficacy at a low concentration when combined with
PDT. The existing PDT and photoactive reports on CU suggest that CU can be used as a potential and
promising natural PS in PDT. In conclusion, CU can be a potent photosensitiser in the treatment of
cancer and skin infections. Therefore, investigating the photodynamic potential of CU derivatives
in terms of higher absorption and extinction coefficient will contribute to the increased efficacy of
photodynamic toxicity.
5.4. Alkaloids
Alkaloids, a diverse secondary metabolites group from higher plants, contain a heterocyclic
structure with a nitrogen atom in the ring [136]. Nitrogen-containing alkaloids are normally photoactive
in nature, e.g., quinine and cinchonamine. The alkaloids were reported for many significant properties,
such as analgesic and anticancer activity [136–139]. The alkaloids camptothecin and vinblastine
are few alkaloids were successfully utilised as chemotherapeutic drugs [138,140]. The anticancer
activity of alkaloids was proved by different studies by means of disturbing tumour progression by
induction of cell cycle arrest at the G1 or G2/M phases, regulating cyclin-dependent kinase (CDK) and
promoting apoptosis as well as autophagy in tumour cells. Furthermore, these compounds induce
apoptosis by regulating Bax, Bcl-2, Bcl-xL, NF-κB and various caspase proteins [140–143]. In addition,
the combination of alkaloids with chemotherapeutic drugs and irradiation also enhanced the biological
activities [144,145]. Furthermore, alkaloids induce the formation of intracellular ROS in cancer cells,
which leads to the destruction of cancer cell metabolism [140–143]. The photochemically best-known
alkaloid is berberine; Luiza Andreazza et al. [146], Bhattacharyya et al. [147] and Inbaraj et al. [81]
reported the antitumour activity of berberine upon UV and blue light irradiation. The irradiation of
berberine at 410 nm proved to be effective in controlling brain cancer cell growth [146]. Beta-carboline
and harmine are also a noticeable alkaloid with a photoactive nature and are reported to produce a
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significant amount of ROS after irradiation [148], which is considered an important feature of potent
PSs. The photoactivity of harmine was proved by the UVA (long-wave ultraviolet radiation) irradiation
against tumour cell lines [148]. Berberine was extensively investigated as a potential photosensitising
agent for PDT [149–151]. The fluorescent active nature of berberine is indicated for its efficiency in
PDT [149]; thus, berberine and its associated alkaloids can be used as a new candidate for photodynamic
therapy [150]. Different studies have proved the photosensitising as well as ROS generation ability
of alkaloids in the presence of a light source [151]. Therefore, berberine can be studied as a natural
photosensitiser in PDT applications with minimal side effects.
5.5. Anthraquinones (AQ)
Anthraquinone are the largest group among natural quinones from higher plants, which, including
naphthoquinones and benzoquinones, includes over 700 compounds, including emodin, physcion,
catenarin and rhein [152,153]. The hydroxylation pattern, however, dictates the possibility of AQs’
photopharmacological properties. Notably, AQs’ aminoanthraquinone derivatives were studied
extensively for their photoactive properties among the plant compounds due to their UV/vis absorption
and photosensitising nature [154,155]. The AQs were reported as kinase and tyrosinase inhibitors
as well as cytotoxicity agents. The M. elliptica AQs such as morindone, soranjidiol and rubiadin
were also reported for their antitumour activity against lymphocytic leukaemia (P-388) cells [156].
The anthraquinones isolated from H. pustulata leaves and stem exhibited photosensitising properties
by generation of singlet oxygen and/or superoxide anion radicals [157]. Comini et al. [158] reported
that irradiation of AQs (soranjidiol and rubiadin) under visible radiation of 380–480 nm can promote
the anti-proliferative effect on MCF-7 breast cancer cells. In addition, Montoya et al. [157] and Vittar et
al. [159] also reported photosensitisation effects of AQs in Balb/c mice and their leukocyte-inhibiting
ability in a dose-dependent manner by inducing apoptosis, necrosis, or autophagy. These study
results show the photoactive nature of AQs to inhibit the proliferation of cancerous cells. Based on the
previous studies and the above data, molecular targets responsible for the anticancer activity of AQs
and major phytocompounds are summarised in Figure 4.
6. Theorical Studies for Assessing the Photoactivity of Natural Compounds
The development of various antitumor compounds with different molecular targets initiated an
exciting field of investigation with recently developed theoretical studies. The theoretical studies
including density functional theory (DFT) and time-dependent density functional theory (TD-DFT)
were used to assess a series of photophysical properties, including absorption spectra, excitation
energies (singlet and triplet) and spin–orbit matrix elements. All the reported compounds are potential
UVA chemotherapeutic agents which require the lowest triplet-state energy for producing highly
cytotoxic ROS [160,161].
7. Advantages and Scope of Natural PSs
The anticancer property of many plant extracts and bioactive compounds have been analysed,
but not so much in terms of as sources of photosensitisers. Selecting proper PSs is the first step in
PDT, and, to date, only a few PSs are clinically approved, such as Photofrin, Foscan and Levulan.
The present study explored the common photoactive nature of various phytocompounds. Many of the
natural photoactive compounds were reported for their non-toxicity against normal cells and toxicity
towards cancer cells. The important property of a PS is the nontoxic nature during the absence of
light. The increasing activity of extracts or phytocompounds after irradiation by light makes them
good photosensitising candidates for PDT. Another important feature that makes photoactive plant
compounds suitable photosensitisers is their absorption maxima at 400–700 nm, which is biologically
compatible. The selective nature of these compounds is important in clinical PDT to overcome side
effects. Future studies are warranted to isolate and evaluate these specific photoactive compounds
from plants to be used as a potent PSs for PDT for cancer and related disorders [162,163].
Molecules 2020, 25, 4102 14 of 22
8. Conclusions and Future Perspectives
As discussed in this review, plant-based photoactive compounds can be used as a natural PSs in
PDT application. There are wide range of unknown natural compounds with different photoactive and
phototoxic properties. This review summarises and encourages researchers to identify and elucidate
natural photoactive plant-based compounds and to use them as alternatives for the synthesis PSs for a
better PDT outcome. Furthermore, discovering natural phototoxic agents as PSs will be helpful to
reduce toxicity and side effects and improve selectivity. In conclusion, use the plant-based PSs in PDT
typically causes less and minimal adverse effects than other treatments that are commonly used in
cancer therapies.
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